QSAM Biosciences Net debt/EBITDA
Cos'è Net debt/EBITDA di QSAM Biosciences?
Net debt/EBITDA di QSAM Biosciences, Inc. è 2.75
Qual è la definizione di Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA di aziende nel Health Care settore su OTC rispetto a QSAM Biosciences
Cosa fa QSAM Biosciences?
QSAM Biosciences, Inc., a clinical stage biotechnology company, develops drugs for the treatment of bone cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage novel radiopharmaceutical for the treatment of bone cancer and related diseases. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was founded in 2004 and is based in Austin, Texas.
Aziende con net debt/ebitda simili a QSAM Biosciences
- International Housewares Retail ha Net debt/EBITDA di 2.75
- DGL ha Net debt/EBITDA di 2.75
- Novabay Pharmaceuticals Inc ha Net debt/EBITDA di 2.75
- Barksdale Capital ha Net debt/EBITDA di 2.75
- Braemar Shipping Services plc ha Net debt/EBITDA di 2.75
- Goldstream Investment ha Net debt/EBITDA di 2.75
- QSAM Biosciences ha Net debt/EBITDA di 2.75
- Nanoxplore Inc ha Net debt/EBITDA di 2.75
- DelMar Pharmaceuticals ha Net debt/EBITDA di 2.76
- Marathon Oil ha Net debt/EBITDA di 2.76
- Resmed ha Net debt/EBITDA di 2.76
- Zeotech ha Net debt/EBITDA di 2.76
- Southern Copper ha Net debt/EBITDA di 2.76